Recro Pharma Inc (NASDAQ:REPH) saw a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 652,600 shares, a decline of 8.4% from the June 30th total of 712,300 shares. Approximately 3.7% of the company’s shares are sold short. Based on an average daily volume of 221,700 shares, the days-to-cover ratio is presently 2.9 days.

Shares of Recro Pharma stock traded down $0.40 during trading hours on Thursday, reaching $10.75. 163,500 shares of the company were exchanged, compared to its average volume of 301,603. Recro Pharma has a 1 year low of $5.49 and a 1 year high of $11.85. The stock’s fifty day moving average is $10.11 and its 200 day moving average is $9.10. The firm has a market cap of $246.48 million, a PE ratio of -4.32 and a beta of -0.27.

Recro Pharma (NASDAQ:REPH) last posted its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.29. Recro Pharma had a negative return on equity of 472.52% and a negative net margin of 64.26%. The business had revenue of $31.26 million for the quarter, compared to analyst estimates of $24.06 million. As a group, sell-side analysts forecast that Recro Pharma will post -0.35 earnings per share for the current year.

In other news, Director Arnaud Ajdler bought 40,000 shares of the business’s stock in a transaction on Friday, May 17th. The shares were bought at an average price of $9.00 per share, with a total value of $360,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 20.10% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of the company. Nuveen Asset Management LLC acquired a new position in shares of Recro Pharma during the second quarter worth $3,455,000. BlackRock Inc. grew its stake in shares of Recro Pharma by 14.9% during the second quarter. BlackRock Inc. now owns 1,292,173 shares of the specialty pharmaceutical company’s stock worth $13,142,000 after purchasing an additional 167,346 shares in the last quarter. Wedge Capital Management L L P NC acquired a new position in shares of Recro Pharma during the second quarter worth $1,682,000. Penn Capital Management Co. Inc. acquired a new position in shares of Recro Pharma during the second quarter worth $1,525,000. Finally, Cadence Capital Management LLC acquired a new position in shares of Recro Pharma during the first quarter worth $803,000. 57.58% of the stock is currently owned by institutional investors and hedge funds.

REPH has been the topic of a number of recent research reports. Zacks Investment Research raised Recro Pharma from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research report on Thursday. BidaskClub raised Recro Pharma from a “hold” rating to a “buy” rating in a research report on Wednesday. Oppenheimer set a $20.00 price objective on Recro Pharma and gave the stock a “buy” rating in a research report on Friday, August 9th. Finally, ValuEngine raised Recro Pharma from a “hold” rating to a “buy” rating in a research report on Friday, May 24th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $12.70.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Featured Article: What is Blockchain?

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.